India, June 16 -- Tuesday, Moderna, Inc. (MRNA) announced several significant changes to its operating model to support its short- and long-term business goals to become a diversified, multi-modality biotechnology company.
As part of the move, the company plans the potential launch of up to three new products in 2027 and 2028, including flu plus COVID combination, seasonal flu and norovirus vaccines. It also expects important clinical milestones this year, including potential pivotal data readouts for its investigational individualized neoantigen therapy and rare genetic disease propionic acidemia therapeutic.
In light of these plans, Stephen Hoge, President of Moderna, will assume oversight of operational and cross-functional leadership ...